18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
Rows of laboratory glass vials, for the most researched peptides of 2026

The 10 most researched peptides in 2026, and what the evidence actually shows

“Most researched” is not the same as “most talked about”. Plenty of peptides with a loud following have a handful of animal studies behind them, while the ones with thousands of patients in published trials rarely trend. This list is ordered by how much real research exists, not by how often a compound appears in a gym conversation, and each entry says what you can and cannot read into the evidence.

Everything here is available in South Africa, and each one links to the page where you can compare options by price per mg.

The most researched peptides in 60 seconds

  • The list is ordered by how much real research exists, not by how often a compound is talked about.
  • The three GLP-1 compounds sit at the top, with large published trial programmes.
  • BPC-157 is heavily discussed but its research is overwhelmingly in animals.
  • Everything on the list is available in South Africa, with options compared by price per mg.

1. Semaglutide

The most heavily studied peptide on this list by a wide margin, with large weight and cardiovascular outcome trials behind it, such as STEP 1 and SELECT, and regulatory approval in multiple countries for the branded products built on it. Research looked at appetite, glucose control and body weight. The evidence base is the reason it became the reference point every newer GLP-1 is compared against. Semaglutide in South Africa.

2. Tirzepatide

A dual agonist, acting at both the GLP-1 and GIP receptors, with its own large published trial programme. In SURMOUNT-5, a head-to-head trial against semaglutide, it averaged 20.2% weight loss at 72 weeks against 13.7%. Two receptors instead of one is the whole design idea, and counting the receptors is the quickest way to keep the three straight. Tirzepatide in South Africa.

3. Retatrutide

The newest of the three and the least settled. It adds a third receptor, glucagon, and its published phase 2 results reported the largest average weight change of the group. It is still investigational, which means the long-term safety record the other two are building does not exist for it yet. Retatrutide week by week covers what the trials actually reported, and retatrutide in South Africa compares the listings.

4. BPC-157

Probably the most discussed recovery peptide anywhere, and the clearest example of the gap between attention and evidence. The research is extensive but overwhelmingly in animals, covering tendon, gut and soft tissue healing. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, 35 of them preclinical and one a small retrospective clinical report, and no clinical safety data. That does not make it uninteresting; it makes the honest summary “promising in rodents, largely untested in people”. BPC-157 in South Africa.

5. TB-500

A synthetic fragment related to thymosin beta-4, researched alongside BPC-157 often enough that people assume they are interchangeable. They are not: different molecules, different mechanisms, frequently studied in the same injury models. BPC-157 vs TB-500 sets them apart properly. TB-500 in South Africa.

6. GHK-Cu

The copper peptide, and the one entry here with a genuine cosmetic science literature rather than a research-only one. Studies looked at collagen, skin firmness and wound repair, and it has been used in commercial skincare for years. Topical and injectable research are not the same thing and should not be read across. What the copper peptide does, and GHK-Cu in South Africa.

7. CJC-1295 with Ipamorelin

Two growth hormone secretagogues usually researched as a pair, because they act on different receptors and the combination was studied for that reason. The published work is mostly older and small, focused on growth hormone release rather than on outcomes people care about. CJC-1295 and Ipamorelin in South Africa.

8. MOTS-c

A mitochondrial-derived peptide, which is a relatively recent category in its own right. Research centres on metabolism and exercise capacity, largely in animal models, with human data limited. Interesting because of where it comes from rather than because of what it has been shown to do in people. MOTS-c in South Africa.

9. SS-31

Also known as elamipretide, and the one here that has been through serious clinical trials under a pharmaceutical programme rather than circulating as a research chemical first. Studies targeted mitochondrial disease and muscle function, with mixed results across endpoints. In September 2025 the FDA granted elamipretide accelerated approval, as Forzinity, for Barth syndrome, a rare inherited condition, in people weighing at least 30 kg, based on improved knee muscle strength rather than a proven clinical benefit. It is not approved for any other use, and that approval says nothing about the research product sold as SS-31. Worth knowing precisely because the trial record is public and not uniformly positive. Browse peptides researched for energy.

10. Semax and Selank

A pair from Russian research institutes, studied there for decades for attention and anxiety respectively, with most of the literature published in Russian and little replicated in Western trials. That is not a reason to dismiss them, but it is a reason to be careful about how confidently anyone summarises them in English. Semax vs Selank.

How to read a list like this

Three questions separate the entries worth your attention from the ones worth your scepticism. Were the studies in people or in animals? How many participants, and over how long? And did the research measure something that matters, or a marker that stands in for it? How to read a peptide study walks through all three without assuming a science degree.

If you are starting from the goal rather than the compound, shop by goal works backwards from what you are trying to do. If you want the full catalogue with live prices per mg, that is on the peptides in South Africa page.

Research products on this site are sold for research use only. Nothing here is a recommendation, a protocol or medical advice.

Browsing by goal? See peptides for focus and mood.

Sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
  2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232.
  3. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36.
  4. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
  5. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21(4):485-495.
  6. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987.
  7. FDA grants accelerated approval for the first treatment for Barth syndrome, Forzinity (elamipretide), 19 September 2025. Drugs.com MedNews summary.
  8. Neznamov GG, et al. Novel anxiolytic Selank: results of the phase II clinical trials (conference abstract). Eur Neuropsychopharmacol 2005;15(Suppl 3):S159-S160.